Glow-in-the-Dark dye could help surgeons spot hidden prostate cancer

NCT ID NCT06434909

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 2 trial tested an imaging dye called Cytalux (pafolacianine) in 9 men with prostate cancer. The dye is injected before surgery and makes cancer cells glow under near-infrared light, helping surgeons see and remove all cancerous tissue during prostate removal. The goal was to see if this technique finds cancer that standard methods might miss.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Cytalux (pafolacianine) injection
What this could lead to
If successful, this imaging agent could help surgeons remove more prostate cancer during surgery, potentially reducing the chance of leftover cancer.
What could go wrong
This is a very small, early-phase study with only 9 participants. The results may not apply to all prostate cancer patients, and the imaging agent may not improve outcomes in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • IU Health Joe and Shelly Schwarz Cancer Center

    Carmel, Indiana, 46032, United States

  • Indiana University Health Melvin and Bren Simon Comprehensive Cancer Center

    Indianapolis, Indiana, 46202, United States

  • Indiana University Health Methodist Hospital

    Indianapolis, Indiana, 46202, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.